Saturday 17 October 2026
Export XLO’s income statement to Excel — free account
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, up 589.9% from fiscal 2024. In the quarter to June 2026, revenue grew 131.2%, EPS grew 85.3% and free cash flow fell 26.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
8.77
0.25
−2.77%
Follow XLO
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | — | (9.15) | (3.34) |
P/S ratio |
— | — | — | — | — | — | 0.00 | 1.71 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (19.94) | (6.58) |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | (3.61) | (37.49) |
P/B ratio |
— | — | — | — | — | — | 2.90 | 2.12 |
Price to Tangible BV |
— | — | — | — | — | — | 2.90 | 2.12 |
EV/Sales |
— | — | — | — | — | — | 0.00 | (1.40) |
EV/EBITDA |
— | — | — | — | — | — | 0.04 | 1.51 |
EV/Operating CF |
— | — | — | — | — | — | 0.14 | 12.24 |
EV/FCF |
— | — | — | — | — | — | 0.14 | 11.09 |
Quick Ratio |
— | 9.38 | 0.87 | 15.50 | 5.70 | 2.80 | 2.03 | 2.53 |
Current Ratio |
— | 9.81 | 0.93 | 15.85 | 5.90 | 3.02 | 2.21 | 2.58 |
Net Debt/EBITDA |
— | 1.61 | 0.22 | 2.56 | 1.34 | 0.58 | 0.94 | 3.40 |
Debt/Assets |
0.00% | 29.70% | 20.41% | 4.42% | 2.27% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.48 | (1.40) | 0.05 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.39 |
Operating CF/Net income |
— | 1.04 | 0.65 | 1.07 | 0.86 | 0.90 | 0.32 | 0.14 |
Capex/Depreciation |
— | 0.00 | (2.05) | (0.73) | (1.01) | (0.26) | (0.02) | (0.34) |
| — | 30.69% | 97.90% | (148.42%) | (60.62%) | (107.25%) | (214.02%) | (132.53%) | |
| — | (55.20%) | (111.51%) | (59.60%) | (49.39%) | (76.37%) | (88.24%) | (31.04%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (31.04%) | (951.72%) | (38.41%) | (79.74%) | (200.47%) | (155.54%) | (37.82%) |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | 41.70 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 649.61% | 128.04% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 390.57% | 67.88% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 101.42% | 15.85% |
Graham Net Nets |
— | — | — | — | — | — | 0.13 | 0.34 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (134.08%) | (59.63%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (36.03%) | (7.36%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.66 | 5.24 |
Operating CF per Share |
— | (0.66) | (965.00) | (201.73) | (38.72) | (34.95) | (4.81) | (0.60) |
Capex per Share |
— | 0.00 | (58.50) | (2.75) | (0.95) | (0.25) | (0.01) | (0.06) |
Free Cash Flow per Share |
— | (0.66) | (1,023.50) | (204.47) | (39.67) | (35.20) | (4.82) | (0.66) |
Cash per Share |
— | 1.78 | 514.39 | 494.76 | 61.55 | 22.77 | 14.47 | 16.45 |
Shareholders Equity per Share |
— | 1.40 | (141.31) | 463.23 | 54.02 | 18.76 | 4.60 | 4.22 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 1.40 | (141.31) | 463.23 | 54.02 | 18.76 | 4.60 | 4.22 |
Free Cash Flow |
— | (18.03) | (38.28) | (81.85) | (77.59) | (69.11) | (18.41) | (5.51) |
Working Capital |
— | 45.90 | (1.56) | 189.74 | 103.38 | 32.17 | 32.97 | 88.75 |
Capital Expenditures |
— | (0.71) | (2.19) | (1.10) | (1.87) | (0.49) | (0.04) | (0.52) |
Net Current Asset Value |
— | 26.89 | (21.01) | 169.89 | 90.98 | 24.03 | 6.76 | 25.62 |
EV/EBIT |
— | — | — | — | — | — | 0.04 | 1.46 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.02 | 0.14 | 0.20 | 0.25 | 0.32 | 0.37 | 0.40 |
Cash ROIC |
— | (17.01%) | (179.17%) | (20.82%) | (33.85%) | (84.76%) | (25.26%) | (3.19%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 3,829.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 3.98 | 3.98 | 4.29 | 3.13 | 2.09 | 1.81 | 2.87 |
Average Assets |
— | 31.36 | 49.52 | 127.19 | 178.61 | 100.05 | 66.00 | 112.88 |
Average Common Equity |
— | (56.40) | (56.40) | 51.07 | 145.54 | 71.24 | 27.21 | 26.44 |
Columns are period end dates